Stock comparison
Haemonetics
Sarepta Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
SRPT
Sarepta Therapeutics
Market cap
$1.77B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | SRPT | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 40D | HAE |
| Benjamin Graham | 85A | 47D | HAE |
| Philip Fisher | 60C | 51C | HAE |
| Peter Lynch | 54C | 59C | SRPT |
| Joel Greenblatt | 31F | 7F | HAE |
| Charlie Munger | 54D | 39D | HAE |
| Terry Smith | 55D | 33F | HAE |
Side-by-side metrics
| Metric | HAE | SRPT |
|---|---|---|
| Market cap | $2.98B | $1.77B |
| P/E (TTM) | 24.8x | 31.3x |
| EV/EBIT | 14.1x | - |
| ROIC (TTM) | 8.37% | -1.53% |
| Gross margin | 55.74% | 62.39% |
| Net margin | 7.29% | 2.98% |
| Revenue CAGR 5y | 7.65% | 33.03% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- ROIC (TTM)8.37%vs -1.53%+118%
- Net margin7.29%vs 2.98%+59%
- Market cap$2.98Bvs $1.77B+40%
- P/E (TTM)24.8xvs 31.3x+21%
SRPT leads on
- EV/EBIT-vs 14.1x+128%
- Revenue CAGR 5y33.03%vs 7.65%+77%
- Debt / Equity0.7xvs 1.5x+55%
- Gross margin62.39%vs 55.74%+11%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.